Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

Journal of Immunotherapy

Volumn 32, Issue 2, 2009, Pages 169-180

  Hollyman, Daniel ^a   Stefanski, Jolanta ^a   Przybylowski, Mark ^a   Bartido, Shirley ^a   Borquez Ojeda, Oriana ^a   Taylor, Clare ^a   Yeh, Raymond ^d   Capacio, Vanessa ^a   Olszewska, Malgorzata ^a   Hosey, James ^a   Sadelain, Michel ^a,b,c,d   Brentjens, Renier J ^b,d   Rivière, Isabelle ^b,c,d  

^a Gene Transfer and Somatic Cell Engineering Facility   (United States)

^b Center for Cell Engineering   (United States)

^c Molecular Pharmacology and Chemistry Program   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Autologous T cells; Biologic activity in vitro and in vivo; Bioreactor; Chimeric antigen receptor; Dynabeads CD3 CD28; Gammaretroviral vector; Large scale expansion; Phase I clinical trial; Validation

Indexed keywords

CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; BURKITT LYMPHOMA; CELL EXPANSION; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA MODIFICATION; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SCID MOUSE; T LYMPHOCYTE; VALIDATION STUDY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOREACTOR; CLINICAL TRIAL; CULTURE TECHNIQUE; CYTOTOXIC T LYMPHOCYTE; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; TRANSPLANTATION;

ANIMALS; ANTIGENS, CD19; BIOREACTORS; CELL CULTURE TECHNIQUES; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; RECEPTORS, ANTIGEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 63649112916     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318194a6e8     Document Type: Article

References (39)

1. Johnson AJ, Mone AP, Abhyankar V, et al. Advances in the therapy of chronic lymphocytic leukemia. Curr Opin Hematol. 2003;10:297-305.
2. Frassoni F, Barrett AJ, Granena A, et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol. 1988;70: 317-320.
3. Barrett AJ, Locatelli F, Treleaven JG, et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT leukaemia working party. Br J Haematol. 1991;79:567-574.
4. Michallet M, Tanguy ML, Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the societe francaise de greffe de moelle (SFGM). Br J Haematol. 2000; 108:400-407.
5. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23: 2346-2357.
6. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
7. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lympho-ma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261-2271.
8. + T cells against NY-ESO-1. N Engl J Med. 2008;358:2698-2703.
9. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous anti-tumor lymphocytes. Proc Natl Acad Sci USA. 2004; 101 (suppl 2):14639-14645.
10. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
11. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
12. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13 (18 Pt 1): 5426-5435.
13. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA. 1995;92:6733-6737.
14. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20:70-75.
15. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13:1440-1449.
16. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107:1325-1331.
17. Bonyhadi M, Frohlich M, Rasmussen A, et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol. 2005;174:2366-2375.
18. Hami LS, Green C, Leshinsky N, et al. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy. 2004;6:554-562.
19. Rapoport AP, Levine BL, Badros A, et al. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant. 2004;33:53-60.
20. +-selected hematopoietic cell transplantation. Blood. 2003;102:2004-2013.
21. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11: 1230-1237.
22. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med. 2002;8:47-53.
23. + T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother. 1998;7:437-448.
24. + infected patients grouped according to CD4 count and viral load. Mol Ther. 2004;9: 902-913.
25. Kalamasz D, Long SA, Taniguchi R, et al. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J Immunother. 2004;27:405-418.
26. Neurauter AA, Bonyhadi M, Lien E, et al. Cell isolation and expansion using Dynabeads. Adv Biochem Eng Biotechnol. 2007;106:41-73.
27. Stefanski J, Brentjens RJ, Hollyman D, et al. CD19-targeted normal and CLL patient T Cells expanded with Beads can eradicate systemic tumors in vivo. Mol Ther. 2006;13:S102.
28. Przybylowski M, Hakakha A, Stefanski J, et al. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Ther. 2006;13:95-100.
29. Tran CA, Burton L, Russom D, et al. Manufacturing of large numbers of patient-specific T cells for adoptive immuno-therapy: an approach to improving product safety, composition, and production capacity. J Immunother. 2007;30:644-654.
30. Quintas-Cardama A, Yeh RK, Hollyman D, et al. Multi-factorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther. 2007; 18:1253-1260.
31. Guidance for Industry for the Supplemental Guidance on Testing for Replication Competent Retrovirus in retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vector. Center for Biologics Evaluation and Research. Food and Drug Administration, US Department of Health and Human Services. November 2006.
32. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services, July 1993.
33. Gee AP, Sumstad D, Stanson J, et al. A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. Cytotherapy. 2008;10:427-435.
34. Choi YW, Kotzin B, Herron L, et al. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci USA. 1989;86:8941-8945.
35. Genevee C, Diu A, Nierat J, et al. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol. 1992;22:1261-1269.
36. Kipps T, Castro E, Wierda WMK. A phase I/II trial of Xcellerated T cells in patients with chronic lymphocytic leukemia. Blood. 2003;102:109a.
37. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763.
38. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224.
39. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008; 118:294-305.